Pfizer Inc. has big ambitions for tafamidis as it launches the new drug in a rare cardiovascular indication, but the commercial ramp up is expected to be slow and success will depend on the company's ability to build disease awareness and diagnosis.
Tafamidis was approved by the US FDA, two months ahead of the July action date, in two oral formulations and will be marketed as Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce cardiovascular mortality and cardiovascular-related
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?